Figure S3


A
Number of new lineages
Binding specificity
WEV
W
E
V
WEEV
IgG endpoint titer
(1/dilution)
Wk2 1.35 x10^5
Wk21 1.45 x10^4
Wk23 2.19 x10^5
Wk30 5.55 x10^4
Wk32 1.53 x10^5
B
Percentage of sequences
Time (weeks)
mAb specificity
WEVEEV
WEEV
EEEV
VEEV
C
Sort
Wk0
Wk8
Wk10
Immunization
Dose (μg)
60
60
D
VLP binding
Pseudovirus neutralization
Specificity
WEEV
EEEV
VEEV
O.D. (450 nm)
IgG endpoint titer (1/dilution)
Subject 1: 1.42 x 10^4
Subject 2: 1.86 x 10^4
Subject 1: 1.29 x 10^4
Subject 2: 1.93 x 10^4
Subject 1: 1.40 x 10^4
Subject 2: 2.42 x 10^4
mAb log10 (ng/mL)
% Inhibition
mAb log10 (μg/mL)
E
Detection mAb
Competitive mAb
WEEV VLP
EEEV VLP
VEEV VLP
SKT05
SKT20
SKT23
hSKT1001
hSKT1002
hSKT1003
hSKT1004
hSKT1006
% Inhibition
0
50
100
F
SINV-WEEV
SINV-EEEV
SINV-VEEV
Median fluoresence intensity
SKT05
SKW11
SKE26
SKV09
hSKT1001
hSKT1002
hSKT1003
hSKT1004
hSKT1006
Control